Robak T
Department of Pharmacology, Medical Academy, Lódź.
Arch Immunol Ther Exp (Warsz). 1988;36(1):71-84.
The antigenic characteristics of "early" and "late" granulocyte-macrophage progenitor cells (CFU-GM) from normal bone marrow (NBM) and normal peripheral blood (NPB) were studied using 14 selected murine monoclonal antibodies (McAbs) in a complement dependent cytotoxicity assay followed by culture in methyl cellulose. The same panel of McAbs was used to determine the antigens on leukaemic colony-forming cells (CFU-L) from the blood of 14 patients with acute myeloid leukaemia (AML). McAbs L243 (anti-HLA-DR antigen), MY9, S3-13 and S17-25 were cytotoxic almost completely with CFU-GM from NBM as well as from NPB, McAbs R1, B19 and WGHS 29.1 reacted with a high percentage of NBM CFU-GM but not with those from NPB. The antigens expressed on normal CFU-GM were also found on the CFU-L in the majority of patients. However, PMN29 reacted strongly with "late" CFU-GM from NBM and did not react with CFU-L. In contrast, some of the McAbs (S4-7, VIM-2) recognized the antigens on a much higher proportion of CFU-L than "early" CFU-GM from NBM. The expression of the majority of the antigens on leukaemic clonogenic cells tends to vary between different patients and also between the different cells of an individual patient. We conclude that some of the McAbs could be used in the further investigations for their usefulness in the treatment of selected patients with AML, for example in the immunoseparation of leukaemic stem cells of an individual patient.
使用14种选定的鼠单克隆抗体(McAbs),在补体依赖性细胞毒性试验中,随后在甲基纤维素中培养,研究了来自正常骨髓(NBM)和正常外周血(NPB)的“早期”和“晚期”粒细胞-巨噬细胞祖细胞(CFU-GM)的抗原特性。同一组McAbs用于确定14例急性髓性白血病(AML)患者血液中白血病集落形成细胞(CFU-L)上的抗原。McAbs L243(抗HLA-DR抗原)、MY9、S3-13和S17-25对来自NBM以及NPB的CFU-GM几乎具有完全细胞毒性,McAbs R1、B19和WGHS 29.1与高比例的NBM CFU-GM反应,但不与NPB来源的CFU-GM反应。在大多数患者的CFU-L上也发现了正常CFU-GM上表达的抗原。然而,PMN29与来自NBM的“晚期”CFU-GM强烈反应,而不与CFU-L反应。相反,一些McAbs(S4-7、VIM-2)识别的CFU-L上的抗原比例比来自NBM的“早期”CFU-GM高得多。白血病克隆形成细胞上大多数抗原的表达在不同患者之间以及单个患者的不同细胞之间往往有所不同。我们得出结论,一些McAbs可用于进一步研究,以确定它们在治疗特定AML患者中的有用性,例如在单个患者白血病干细胞的免疫分离中。